Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Polyclonal Antibody

Anti-Lassa virus/LASV GPC Polyclonal Antibody

Catalog #:   PVV04301 Specific References (45) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: ELISA, IHC, WB
Accession: P08669
Overview

Catalog No.

PVV04301

Species reactivity

Lassa virus (strain Mouse/Sierra Leone/Josiah/1976) (LASV)

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Lassa virus/LASV GPC (Thr59-Leu259).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:200, WB: 1:500-1:4000

Target

Pre-glycoprotein polyprotein GP complex, Pre-GP-C, Stable signal peptide, SSP, Glycoprotein G1, GP1, Glycoprotein G2, GP2, GPC, GP-C

Concentration

0.84 mg/ml

Purification

Purified by antigen affinity column.

Accession

P08669

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Data Image
  • WESTERN-BLOT
    Recombinant Protein lysates were subjected to SDS PAGE followed by western blot with GPC antibody (PVV04301) at 1 μg/ml.

    Lane 1: Recombinant protein

    Second Ab: Goat Anti-Rabbit IgG H&L Polyclonal antibody, HRP (PTB96431) at 0.1 μg/mL.

    Predict MW: 25 kDa
    Observed MW: 25 kDa
References

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever., PMID:40367816

Mapping the antibody response to Lassa virus vaccination of non-human primates., PMID:40168843

Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials., PMID:40157130

Structure-guided design of a prefusion GPC trimer induces neutralizing responses against LASV., PMID:39987102

Conformational ensemble-based framework enables rapid development of Lassa virus vaccine candidates., PMID:39605488

Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses., PMID:39243373

Deep mutational scanning reveals functional constraints and antibody-escape potential of Lassa virus glycoprotein complex., PMID:39013466

Deep mutational scanning reveals functional constraints and antigenic variability of Lassa virus glycoprotein complex., PMID:38370709

Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses., PMID:38187682

Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability., PMID:38177144

Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies., PMID:37209096

Deletion of the first glycosylation site promotes Lassa virus glycoprotein-mediated membrane fusion., PMID:37059226

Holding it together: Nanoparticle stabilization of LASV trimer., PMID:36521442

Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection., PMID:36400021

A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus., PMID:36288283

Lassa Virus Countermeasures., PMID:36253593

Neutralizing Antibodies against Lassa Virus Lineage I., PMID:35730904

Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies., PMID:35613585

Construction and Immunological Evaluation of an Adenoviral Vector-Based Vaccine Candidate for Lassa Fever., PMID:33804206

Effects of N-Linked Glycan on Lassa Virus Envelope Glycoprotein Cleavage, Infectivity, and Immune Response., PMID:33689141

ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge., PMID:33654106

Identification of Common CD8+ T Cell Epitopes from Lassa Fever Survivors in Nigeria and Sierra Leone., PMID:32269122

A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge., PMID:31466243

Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization., PMID:31398326

Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques., PMID:31071008

Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever., PMID:30310067

Structure of the Lassa virus glycan shield provides a model for immunological resistance., PMID:29941589

Lassa virus glycoprotein: stopping a moving target., PMID:29843991

Antibodies to the Glycoprotein GP2 Subunit Cross-React between Old and New World Arenaviruses., PMID:29720525

Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development., PMID:29581897

Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins., PMID:29287681

An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions., PMID:28797730

Structural basis for antibody-mediated neutralization of Lassa virus., PMID:28572385

Structure-function relationship of the mammarenavirus envelope glycoprotein., PMID:27562602

Shedding of soluble glycoprotein 1 detected during acute Lassa virus infection in human subjects., PMID:21062490

Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever., PMID:20961433

Uncoupling GP1 and GP2 expression in the Lassa virus glycoprotein complex: implications for GP1 ectodomain shedding., PMID:19105844

Identification of protective Lassa virus epitopes that are restricted by HLA-A2., PMID:16912286

A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins., PMID:16412488

Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones., PMID:15033572

Cross-protection against lymphocytic choriomeningitis virus mediated by a CD4+ T-cell clone specific for an envelope glycoprotein epitope of Lassa virus., PMID:7684468

Simultaneous expression of the Lassa virus N and GPC genes from a single recombinant vaccinia virus., PMID:2042398

Fine mapping of a peptide sequence containing an antigenic site conserved among arenaviruses., PMID:2452517

Site-specific antibodies define a cleavage site conserved among arenavirus GP-C glycoproteins., PMID:3546729

Structural and cell-associated proteins of Lassa virus., PMID:6405010

Datasheet
$ 170
Product specifications
50 μg 170 100 μg 280

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Lassa virus/LASV GPC Polyclonal Antibody [PVV04301]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only